Plant-based specialty polymers and sustainable ingredients
Strategic Profile
The core Itaconix Performance Ingredients business continues to build momentum in consumer detergent applications, where its polymers are used for scale inhibition and odour neutralisation as an alternative to fossil-based specialty chemicals. The company is positioned for first profitability this year with management forecasting revenues of $13.3 million and adjusted EBITDA of $300,000 for the full year 2026. The Group has revenue concentration in three customers of 48%, representing execution risk that warrants monitoring.
Cyborg Score Rationale
In 2025, Itaconix delivered its strongest year of commercial and operational advancement, achieving record revenues of $10.5m, a 61% increase from 2024. The company expects to deliver positive adjusted EBITDA for the first time in 2026 with a clear path confirmed. However, customer concentration at 48% and pre-profitability status temper the score.
Top Insights
EMEA Performance Ingredient revenues reached $3.9m in 2025, up 104% from $1.9m in 2024, driven primarily by increased adoption of scale inhibitors in unit dose dishwashing detergents
Middle Eastern supply disruptions for fossil-based specialty chemicals are driving customer adoption of Itaconix's plant-based alternatives, recognized as a source of competitive advantage in pricing and supply stability
During 2025, the company developed new unit dose detergent formulations for 17 North American brands through its SPARX Formulated Solutions programme and launched an ecommerce platform for BIO*Asterix specialty itaconate monomers
Gross profit rose to $3.6m, with margins stable at 35%, reflecting disciplined pricing, stable raw material costs, and improved operational efficiencies
Named Competitors
Specialty Polymers & Scale Inhibitors — Diversified specialty chemical company with scale inhibition and polymer solutions
Plant-Based Polymers & Sustainability Solutions — Global chemical company competing in sustainable specialty ingredients
Recent Developments
(June 2026) Trading at 111 pence on AIM with market cap approximately $21.7m (as of early March 2026)
(March 2026) Announced 2025 full-year results with record $10.5m revenue, 61% growth, and adjusted EBITDA losses narrowed to $600k
(March 2026) Forecasted $13.3m revenue and $300k positive adjusted EBITDA for 2026, expecting first profitable year
(January 2026) H2 2025 revenues reached $5.5m, third consecutive record half-year, demonstrating sustained commercial momentum
Open the full interactive Itaconix plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.